Skip to main content

Table 5 Disease-related characteristics at baseline, 2 weeks, and 12 weeks

From: The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study

  Baseline 2 weeks 12 weeks Treatment effect
F(2, 22) =
Morning stiffness (min) 116 ± 75 72 ± 81a 55 ± 83a 4.33, P = 0.02
CRP (mg/L) 10 (4-14) 3 (2.9-6)a 5 (2.9-10)a 12.89, P < 0.001
ESR (mm/hr) 16 (9-34) 10 (5-21)a 17 (5-27) 4.98, P = 0.01
DAS28 4.17 ± 0.96 2.74 ± 1.4a 2.64 ± 1.07a 15.92, P < 0.001
HAQ 2.1 ± 0.5 1.3 ± 0.9a 1.3 ± 0.9a 17.18, P < 0.001
  1. Results are expressed as median (25th to 75th percentile values) or mean ± standard deviation, as appropriate. aDifferent from baseline. CRP, C-reactive protein; DAS28, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire.